NovaBridge Biosciences has announced significant updates regarding its investigational drug Givastomig, which is being developed for the treatment of first-line metastatic gastroesophageal adenocarcinoma. The company presented updated Phase 1b data at the European Society for Medical Oncology (ESMO) Congress 2026, showcasing promising results that could lead to registrational development.
On October 25, 2026, NovaBridge revealed that the updated dataset includes nearly 18 months of median follow-up, reinforcing the drug’s potential in the oncology market. This development is particularly important as it positions NovaBridge to compete more effectively within the pharmaceutical preparations sector.
Background
NovaBridge Biosciences operates under the Standard Industrial Classification (SIC) code 2834, focusing on pharmaceutical preparations. The company trades on the Nasdaq under the ticker NBP. Recent filings include a Form 6-K submitted on October 26, 2026, detailing the latest updates on Givastomig and its clinical trials.
What the Filing Says
The filing states, "On October 25, 2026, NovaBridge Biosciences issued a press release, a copy of which is furnished herewith as Exhibit 99.1 to this report." This press release highlights the results of the Phase 1b study, which showed an objective response rate of 79% among efficacy-evaluable patients treated with the 8 mg/kg dose of Givastomig.
Impact
The results from this study may significantly impact patients suffering from HER2-negative first-line metastatic gastroesophageal adenocarcinoma, as they indicate a potential new treatment option. Additionally, the data may influence healthcare providers and investors interested in innovative cancer therapies.
What's Next
NovaBridge plans to host an investor webcast on November 2, 2026, to discuss the updated data and its registrational development strategy. The filing does not specify any further immediate actions beyond this presentation.